Announcement on Change of Sponsor Representative for Continuous Supervision
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Change of Sponsor Representative for Continuous Supervision
Filed with SSE ·
On 6ix: 6ix.com/news/announcement-on-change-of-sponsor-representative-for-continuous-supervision-113
6ix hasn’t read this filing yet.
Jiangsu Yahong Meditech Co., Ltd. on 6ix
Earlier from Jiangsu Yahong Meditech
- Announcement on Correction of Resolution of the 11th Meeting of the 2nd Board of Directors
- Announcement on Voluntary Disclosure of Release of Relevant Data of APL-1702 International Multicenter Phase III Clinical Trial at the 27th National Conference on Clinical Oncology and 2024 Annual Meeting of Chinese Society of Clinical Oncology
- Announcement on Voluntarily Disclosure of Phase II Clinical Trial Results of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer
Later from Jiangsu Yahong Meditech
- Announcement on Voluntary Disclosure of FDA Approval for Clinical Trial of APL-2302
- Announcement on Completion of Industrial and Commercial Registration for Changes in Business Scope and Renewal of Business License
- Announcement on Voluntary Disclosure of Approval for APL-1706 by National Medical Products Administration
- Announcement on Voluntary Disclosure of Releasing Relevant Data of APL-1702 International Multicenter Phase III Clinical Trial at IPVC 2024
- Announcement on Progress in Repurchasing Shares through Call Auction
Follow Jiangsu Yahong Meditech into a list and get an email when it puts out news.
Follow Jiangsu Yahong Meditech